Institutional investors purchased a net $65.0 thousand shares of REGN during the quarter ended March 2017. This may signal that the smart money is gaining interest in this company as the 70.15% of the shares outstanding that institutional investors hold is among the lowest in the Biotechnology industry.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
SANDS CAPITAL MANAGEMENT LLC Bought 630.6 Thousand shares of Regeneron Pharmaceuticals
JANUS CAPITAL MANAGEMENT LLC Bought 488.4 Thousand shares of Regeneron Pharmaceuticals